Who are SARILUMAB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Roactemra, TOCILIZUMAB, TYENNE, AVTOZMA, TOFIDENCE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sarilumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SARILUMAB — Competitive Intelligence Brief

SARILUMAB (SARILUMAB) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-6 Receptor Antagonist [EPC].

marketed Interleukin-6 Receptor Antagonist [EPC] IL-6 receptors (sIL-6R and mIL-6R) Monoclonal antibody Live · refreshed every 30 min

Target snapshot

SARILUMAB (SARILUMAB). Sarilumab inhibits IL-6 signaling by binding to both soluble and membrane-bound IL-6 receptors.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SARILUMAB TARGET	SARILUMAB		marketed	Interleukin-6 Receptor Antagonist [EPC]	IL-6 receptors (sIL-6R and mIL-6R)	2017-01-01
Roactemra	tocilizumab	Roche	marketed	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
TOCILIZUMAB	TOCILIZUMAB		marketed	Interleukin-6 Receptor Antagonist [EPC]		2005-01-01
TYENNE	TOCILIZUMAB-AAZG	FRESENIUS KABI USA	marketed	Interleukin-6 Receptor Antagonist [EPC]
AVTOZMA	TOCILIZUMAB-ANOH	CELLTRION INC	marketed	Interleukin-6 Receptor Antagonist [EPC]
TOFIDENCE	TOCILIZUMAB-BAVI	BIOGEN MA	marketed	Interleukin-6 Receptor Antagonist [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-6 Receptor Antagonist [EPC] class)

· 2 drugs in this class
BIOGEN MA · 1 drug in this class
CELLTRION INC · 1 drug in this class
FRESENIUS KABI USA · 1 drug in this class
Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SARILUMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/sarilumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab